Abstract
Multiple endocrine neoplasia (MEN) indicates a group of familial syndromes characterized by the simultaneous occurrence of tumors in more than one endocrine organ. MEN patients develop tumors of the pancreas, parathyroid, pituitary, adrenal, and thyroid glands, together with various neuroendocrine tumors (NETs) of the respiratory and gastrointestinal tracts. These syndromes are inherited as autosomal dominant traits with high penetrance. There are three recognized MEN syndromes: MEN type 1 (MEN1), MEN2, and MEN4. Each of these syndromes has a specific tumor spectrum and is caused by germline mutation of a different gene: MEN1 patients carry loss-of-function mutations in the MEN1 tumor suppressor gene; MEN2 is associated with activating changes in the RET proto-oncogene; and MEN4 is caused by mutations in CDKN1B encoding the cell cycle inhibitor p27Kip1 (p27).
MEN4 is the most recently discovered syndrome. CDKN1B was identified as susceptibility gene for multiple endocrine tumors based on studies of a rat strain displaying a MEN1-like tumors spectrum (MENX syndrome). MENX-affected rats were found to carry a spontaneous germline inactivating mutation in Cdkn1b. To date only 19 patients with germline CDKN1B mutations have been reported in the literature. The most recurrent MEN4-associated clinical manifestations are primary hyperparathyroidism (1°HPT) and pituitary adenomas. MENX and MEN4 syndromes mostly resemble MEN1; hence they were initially referred to as MEN1-like. This review will focus on the phenotypic features and the genetics of MENX and MEN4 syndromes and will briefly address the role of CDKN1B in tumorigenesis.
This is a preview of subscription content, log in via an institution to check access.
References
Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab. 2009;94:1826–34. https://doi.org/10.1210/jc.2008-2083.
Belar O, De La Hoz C, Perez-Nanclares G, Castano L, Gaztambide S, Spanish MEN1 Group, et al. Novel mutations in MEN1, CDKN1B and AIP genes in patients with multiple endocrine neoplasia type 1 syndrome in Spain. Clin Endocrinol (Oxf). 2012;76:719–24. https://doi.org/10.1111/j.1365-2265.2011.04269.x.
Bencivenga D, Caldarelli I, Stampone E, Mancini FP, Balestrieri ML, Della Ragione F, et al. p27Kip1 and human cancers: a reappraisal of a still enigmatic protein. Cancer Lett. 2017;403:354–65. https://doi.org/10.1016/j.canlet.2017.06.031.
Besson A, Gurian-West M, Chen X, Kelly-Spratt KS, Kemp CJ, Roberts JM. A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression. Genes Dev. 2006;20:47–64.
Borsari S, Pardi E, Pellegata NS, Lee M, Saponaro F, Torregrossa L, et al. Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas. Endocrine. 2017;55:386–97. https://doi.org/10.1007/s12020-016-0941-6.
Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658–71.
Brochier S, Galland F, Kujas M, Parker F, Gaillard S, Raftopoulos C, et al. Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. Eur J Endocrinol/Eur Fed Endocr Soc. 2010;163:193–200.
Castinetti F, Kroiss A, Kumar R, Pacak K, Taieb D. 15 YEARS OF PARAGANGLIOMA: imaging and imaging-based treatment of pheochromocytoma and paraganglioma. Endocr Relat Cancer. 2015;22:T135–45. https://doi.org/10.1530/ERC-15-0175.
Chang BL, Zheng SL, Isaacs SD, Wiley KE, Turner A, Li G, et al. A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. Cancer Res. 2004;64:1997–9.
Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer, prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 2008;8:253–67. https://doi.org/10.1038/nrc2347.
Cohen R, Campos JM, Salaun C, Heshmati HM, Kraimps JL, Proye C, et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d’Etudes des Tumeurs a Calcitonine (GETC). J Clin Endocrinol Metab. 2000;85:919–22. https://doi.org/10.1210/jcem.85.2.6556.
Costa-Guda J, Marinoni I, Molatore S, Pellegata NS, Arnold A. Somatic mutation and germline sequence abnormalities in CDKN1B, encoding p27Kip1, in sporadic parathyroid adenomas. J Clin Endocrinol Metab. 2011;96:E701–6. https://doi.org/10.1210/jc.2010-1338.
Crona J, Gustavsson T, Norlen O, Edfeldt K, Akerstrom T, Westin G, et al. Somatic mutations and genetic heterogeneity at the CDKN1B locus in small intestinal neuroendocrine tumors. Ann Surg Oncol. 2015;22(Suppl 3):S1428–35. https://doi.org/10.1245/s10434-014-4351-9.
de Laat JM, van der Luijt RB, Pieterman CR, Oostveen MP, Hermus AR, Dekkers OM, et al. MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients. BMC Med. 2016;14:182. https://doi.org/10.1186/s12916-016-0708-1.
Dietrich S, Hüllein J, Lee SC, Hutter B, Gonzalez D, Jayne S, et al. Recurrent CDKN1B (p27) mutations in hairy cell leukemia. Blood. 2015;126:1005–8. https://doi.org/10.1182/blood-2015-04-643361.
Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res. 2009;41:697–702. https://doi.org/10.1055/s-0029-1220687.
Elston MS, Meyer-Rochow GY, Dray M, Swarbrick M, Conaglen JV. Early onset primary hyperparathyroidism associated with a novel germline mutation in CDKN1B. Case Rep Endocrinol. 2015;2015:510985. https://doi.org/10.1155/2015/510985.
Fassnacht M, Weismann D, Ebert S, Adam P, Zink M, Beuschlein F, et al. KT is highly phosphorylated in pheochromocytomas but not in benign adrenocortical tumors. J Clin Endocrinol Metab. 2005;90:4366–70. https://doi.org/10.1210/jc.2004-2198.
Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27Kip1-deficient mice. Cell. 1996;85:733–44.
Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature. 1998;396:177–80.
Francis JM, Kiezun A, Ramos AH, Serra S, Pedamallu CS, Qian ZR, et al. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013;45:1483–6. https://doi.org/10.1038/ng.2821.
Fritz A, Walch A, Piotrowska K, Rosemann M, Schäffer E, Weber K, et al. Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Res. 2002;62:3048–51.
Gaertner FC, Wiedemann T, Yousefi BH, Lee M, Repokis I, Higuchi T, et al. Preclinical evaluation of 18F-LMI1195 for in vivo imaging of pheochromocytoma in the MENX tumor model. J Nucl Med. 2013;54:2111–7. https://doi.org/10.2967/jnumed.113.119966.
Gao H, Ouyang X, Banach-Petrosky W, Borowsky AD, Lin Y, Kim M, et al. A critical role for p27Kip1kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci. 2004;101:17204–9. https://doi.org/10.1073/pnas.0407693101.
Georgitsi M, Raitila A, Karhu A, van der Luijt RB, Aalfs CM, Sane T, et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab. 2007;92:3321–5. https://doi.org/10.1210/jc.2006-2843.
Goepfert U, Kullmann M, Hengst L. Cell cycle-dependent translation of p27 involves a responsive element in its 5′-UTR that overlaps with a uORF. Hum Mol Genet. 2003;12:1767–79.
Goudet P, Barlier A. Multiple endocrine neoplasia-type 1 (MEN1): molecular diagnosis and clinical implications. In: Colao A et al., editors. Polyendocrine disorders and endocrine neoplastic syndromes. Springer Nature Switzerland; in press.
Han S, Park K, Kim HY, Lee MS, Kim HJ, Kim YD. Reduced expression of p27Kip1 protein is associated with poor clinical outcome of breast cancer patients treated with systemic chemotherapy and is linked to cell proliferation and differentiation. Breast Cancer Res Treat. 1999;55:161–7.
Hnit SS, Xie C, Yao M, Holst J, Bensoussan A, De Souza P, et al. p27(Kip1) signaling: transcriptional and post-translational regulation. Int J Biochem Cell Biol. 2015;68:9–14. https://doi.org/10.1016/j.biocel.2015.08.005.
Ishida N, Hara T, Kamura T, Yoshida M, Nakayama K, Nakayama KI. Phosphorylation of p27Kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J Biol Chem. 2002;277:14355–8. https://doi.org/10.1074/jbc.C100762200.
Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, et al. A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer. 2002;9:103–13.
Kamura T, Hara T, Matsumoto M, Ishida N, Okumura F, Hatakeyama S, et al. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. Nat Cell Biol. 2004;6:1229–35. https://doi.org/10.1038/ncb1194.
Karnik SK, Hughes CM, Gu X, Rozenblatt-Rosen O, McLean GW, Xiong Y, et al. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci U S A. 2005;102:14659–64. https://doi.org/10.1073/pnas.0503484102.
Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell. 1996;85:721–32.
Landa I, Montero-Conde C, Malanga D, De Gisi S, Pita G, Leandro-García LJ, et al. Allelic variant at -79 (C>T) in CDKN1B (p27Kip1) confers an increased risk of thyroid cancer and alters mRNA levels. Endocr Relat Cancer. 2010;17:317–28. https://doi.org/10.1677/ERC-09-0016.
Lee M, Marinoni I, Irmler M, Psaras T, Honegger JB, Beschorner R, et al. Transcriptome analysis of MENX-associated rat pituitary adenomas identifies novel molecular mechanisms involved in the pathogenesis of human pituitary gonadotroph adenomas. Acta Neuropathol. 2013;126:137–50. https://doi.org/10.1007/s00401-013-1132-7.
Lee M, Wiedemann T, Gross C, Leinhauser I, Roncaroli F, Braren R, et al. Targeting PI3K/mTOR signaling displays potent antitumor efficacy against nonfunctioning pituitary adenomas. Clin Cancer Res. 2015;21:3204–15. https://doi.org/10.1158/1078-0432.CCR-15-0288.
Lee M, Minaskan N, Wiedemann T, Irmler M, Beckers J, Yousefi BH, et al. Targeting PI3K/mTOR signaling exerts potent antitumor activity in pheochromocytoma in vivo. Endocr Relat Cancer. 2017;24:1–15. https://doi.org/10.1530/ERC-16-0324.
Leinhäuser I, Richter A, Lee M, Hofig I, Anastasov N, Fend F, et al. Oncogenic features of the bone morphogenic protein 7 (BMP7) in pheochromocytoma. Oncotarget. 2015;6:39111–26. https://doi.org/10.18632/oncotarget.4912.
Lu Y, Gao K, Zhang M, Zhou A, Zhou X, Guan Z, et al. Genetic association between CDKN1B rs2066827 polymorphism and susceptibility to cancer. Medicine (Baltimore). 2015;94(46):e1217. https://doi.org/10.1097/MD.0000000000001217.
Malanga D, De Gisi S, Riccardi M, Scrima M, De Marco C, Robledo M, et al. Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in a Spanish patient with multiple endocrine neoplasia-like phenotype. Eur J Endocrinol. 2012;166:551–60. https://doi.org/10.1530/EJE-11-0929.
Marinoni I, Lee M, Mountford S, Perren A, Bravi I, Jennen L, et al. Characterization of MENX-associated pituitary tumours. Neuropathol Appl Neurobiol. 2013;39:256–69. https://doi.org/10.1111/j.1365-2990.2012.01278.x.
Maxwell JE, Sherman SK, Li G, Choi AB, Bellizzi AM, O’Dorisio TM, et al. Somatic alterations of CDKN1B are associated with small bowel neuroendocrine tumors. Cancer Genet. 2015. https://doi.org/10.1016/j.cancergen.2015.08.003. S2210-7762 00184-2.
Miederer M, Molatore S, Marinoni I, Perren A, Spitzweg C, Reder S, et al. Functional imaging of pheochromocytoma with Ga-DOTATOC and C-HED in a genetically defined rat model of multiple endocrine neoplasia. Int J Mol Imaging. 2011;175352. https://doi.org/10.1155/2011/175352.
Millard SS, Vidal A, Markus M, Koff A. A U-rich element in the 5′ untranslated region is necessary for the translation of p27 mRNA. Mol Cell Biol. 2000;20:5947–59.
Mohr H, Pellegata NS. Animal models of MEN1. Endocr Relat Cancer. 2017;24:T161–77. https://doi.org/10.1530/ERC-17-0249.
Molatore S, Kiermaier E, Jung CB, Lee M, Pulz E, Hofler H, et al. Characterization of a naturally-occurring p27 mutation predisposing to multiple endocrine tumors. Mol Cancer. 2010a;9:116.
Molatore S, Liyanarachchi S, Irmler M, Perren A, Mannelli M, Ercolino T, et al. Pheochromocytoma in rats with multiple endocrine neoplasia (MENX) shares gene expression patterns with human pheochromocytoma. Proc Natl Acad Sci U S A. 2010b;107:18493–8. https://doi.org/10.1073/pnas.1003956107.
Molatore S, Marinoni I, Lee M, Pulz E, Ambrosio MR, degli Uberti EC, et al. A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization. Hum Mutat. 2010c;31:E1825–35. https://doi.org/10.1002/humu.21354.
Molatore S, Kügler A, Irmler M, Wiedemann T, Neff F, Feuchtinger A, et al. Characterization of neuroendocrine tumors in heterozygous mutant MENX rats: a novel model of invasive medullary thyroid carcinoma. Endocr Relat Cancer. 2018;25:145–62. https://doi.org/10.1530/ERC-17-0456.
Morosetti R, Kawamata N, Gombart AF, Miller CW, Hatta Y, Hirama T, et al. Alterations of the p27KIP1 gene in non-Hodgkin’s lymphomas and adult T-cell leukemia/lymphoma. Blood. 1995;86:1924–30.
Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, et al. Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 1996;85:707–20.
Occhi G, Regazzo D, Trivellin G, Boaretto F, Ciato D, Bobisse S, et al. A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype. PLoS Genet. 2013;9:e1003350. https://doi.org/10.1371/journal.pgen.1003350.
Oh DY, Kim TW, Park YS, Shin SJ, Shin SH, Song EK, et al. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas. Cancer. 2012;118:6162–70. https://doi.org/10.1002/cncr.27675.
Ojeda D, Lakhal B, Fonseca DJ, Braham R, Landolsi H, Mateus HE, et al. Sequence analysis of the CDKN1B gene in patients with premature ovarian failure reveals a novel mutation potentially related to the phenotype. Fertil Steril. 2011;95:2658–60.e1. https://doi.org/10.1016/j.fertnstert.2011.04.045.
Pappa V, Papageorgiou S, Papageorgiou E, Panani A, Boutou E, Tsirigotis P, et al. A novel p27 gene mutation in a case of unclassified myeloproliferative disorder. Leuk Res. 2005;29:229–31. https://doi.org/10.1016/j.leukres.2004.06.007.
Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Höfler H, et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A. 2006;103:15558–63. https://doi.org/10.1073/pnas.0603877103.
Philipp-Staheli J, Payne SR, Kemp CJ. p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res. 2001;264:148–68. https://doi.org/10.1006/excr.2000.5143.
Pippa R, Espinosa L, Gundem G, García-Escudero R, Dominguez A, Orlando S, et al. p27Kip1 represses transcription by direct interaction with p130/E2F4 at the promoters of target genes. Oncogene. 2012;31:4207–20. https://doi.org/10.1038/onc.2011.582.
Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994;78:59–66.
Prado-Montes de Oca E. Human beta-defensin 1: a restless warrior against allergies, infections and cancer. Int J Biochem Cell Biol. 2010;42:800–4. https://doi.org/10.1016/j.biocel.2010.01.021.
Rachdi L, Balcazar N, Elghazi L, Barker DJ, Krits I, Kiyokawa H, et al. Differential effects of p27 in regulation of beta-cell mass during development, neonatal period, and adult life. Diabetes. 2006;55:3520–8. https://doi.org/10.2337/db06-0861.
Rohmer V. Multiple endocrine neoplasia-type 2 (MEN2): molecular diagnosis and clinical implications. In: Colao A et al., editors. Polyendocrine disorders and endocrine neoplastic syndromes. Springer Nature Switzerland; 2019. https://doi.org/10.1007/978-3-319-73082-0_9-1
Romei C, Ciampi R, Elisei R. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat Rev Endocrinol. 2016;12:92–202. https://doi.org/10.1038/nrendo.2016.11.
Sambugaro S, Di Ruvo M, Ambrosio MR, Pellegata NS, Bellio M, Guerra A, et al. Early onset acromegaly associated with a novel deletion in CDKN1B 5′UTR region. Endocrine. 2015;49:58–64. https://doi.org/10.1007/s12020-015-0540-y.
Sekiya T, Bronstein MD, Benfini K, Longuini VC, Jallad RS, Machado MC, et al. p27 variant and corticotropinoma susceptibility: a genetic and in vitro study. Endocr Relat Cancer. 2014;21:395–404. https://doi.org/10.1530/ERC-13-0486.
Serres MP, Zlotek-Zlotkiewicz E, Concha C, Gurian-West M, Daburon V, Roberts JM, et al. Cytoplasmic p27 is oncogenic and cooperates with Ras both in vivo and in vitro. Oncogene. 2011;30:2846–58. https://doi.org/10.1038/onc.2011.9.
Spirin KS, Simpson JF, Takeuchi S, Kawamata N, Miller CW, Koeffler HP. p27/Kip1 mutation found in breast cancer. Cancer Res. 1996;56:2400–4.
Tichomirowa MA, Lee M, Barlier A, Daly AF, Marinoni I, Jaffrain-Rea ML, et al. Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. Endocr Relat Cancer. 2012;19:233–41. https://doi.org/10.1530/ERC-11-0362.
Tomoda K, Kubota Y, Kato J. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature. 1999;98:160–5.
Tonelli F, Giudici F, Giusti F, Marini F, Cianferotti L, Nesi G, et al. A heterozygous frameshift mutation in exon 1 of CDKN1B gene in a patient affected by MEN4 syndrome. Eur J Endocrinol. 2014;171:K7–17. https://doi.org/10.1530/EJE-14-0080.
Wiedemann T, Peitzsch M, Qin N, Neff F, Ehrhart-Bornstein M, Eisenhofer G, et al. Morphology, biochemistry, and pathophysiology of MENX-related pheochromocytoma recapitulate the clinical features. Endocrinology. 2016;157:3157–66. https://doi.org/10.1210/en.2016-1108.
Acknowledgments
The work of the authors is supported by the Deutsche Forschungsgemeinschaft (DFG) within the CRC/Transregio 205/1 “The Adrenal: Central Relay in Health and Disease” (subproject B11) and by the Deutsche Krebshilfe (grant 70112383).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this entry
Cite this entry
Minaskan Karabid, N., Pellegata, N.S. (2019). Multiple Endocrine Neoplasia-Type 4 (MEN4) and Other MEN1-Like Syndromes. In: Colao, A., Jaffrain-Rea, ML., Beckers, A. (eds) Polyendocrine Disorders and Endocrine Neoplastic Syndromes. Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-319-73082-0_10-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-73082-0_10-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-73082-0
Online ISBN: 978-3-319-73082-0
eBook Packages: Springer Reference MedicineReference Module Medicine